Akribion
Akribion Therapeutics develops a programmable cell depletion technology utilizing a proprietary RNA-guided nuclease enzyme payload called G-dase® E. The platform is designed to differentiate between target and healthy cells with single nucleotide specificity by exchanging short guide RNAs. The company is initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC) with further applications in precision oncology.
Visit websiteZwingenberg, Germany
Biotechnology
Oncology
Healthtech
Funding summary
- Total raised
- €8.0M
- Funding rounds
- 1
Investors in Akribion
Investors on record for Akribion. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Akribion?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors